SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma successfully acquires InSite Vision

03 Nov 2015 Evaluate

Sun Pharmaceutical Industries (Sun Pharma) has successfully completed acquistion of InSite Vision Incorporated (InSite). The acquisition was completed by means of a short-form merger under Delaware law. Post the short-form merger, InSite has become an indirect wholly owned subsidiary of Sun Pharma.

As a result of the merger, each issued and outstanding share of InSite common stock (other than shares of InSite common stock owned by the indirect wholly owned subsidiaries of Sun Pharma or InSite (or held in its treasury), any subsidiary of the indirect wholly owned subsidiaries of Sun Pharma or InSite, or by any stockholder of InSite who or which is entitled to and properly demands and perfects appraisal of such shares of InSite common stock pursuant to, and complies in all respects with, the applicable provisions of Delaware law) was converted into the right to receive US$0.35 and each option to acquire shares of InSite common stock that is unexercised and outstanding as of immediately prior to the merger, to the extent not then vested or exercisable, became fully vested and exercisable and was converted into the right to receive a cash payment in an amount equal to the excess, if any, of $0.35 over the exercise price of such option to acquire shares of InSite common stock. 

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.

Sun Pharma Inds. Share Price

1670.85 -4.35 (-0.26%)
20-Apr-2026 14:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.85
Dr. Reddys Lab 1236.40
Cipla 1233.10
Zydus Lifesciences 937.40
Lupin 2329.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×